Clinical Trial Update: Phase 2 Study MPC-6827 for Recurrent Glioblastoma Multiforme [Phase 2]

View source ↗

Summary

Phase 2 study of MPC-6827 for recurrent glioblastoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• MPC-6827

Snippet

Sponsor: Myrexis Inc. | Conditions: Glioblastoma Multiforme | Phase 2 | Status: COMPLETED